Clinicopathological comparison between PTCL-TBX21 and PTCL-GATA3 in Japanese patients.
Yasumasa ShimasakiHiroaki MiyoshiKeisuke KawamotoNoriaki YoshidaTatsuzo MishinaKazutaka NakashimaTeppei ImamotoTakeshi SugioEriko YanagidaTakeharu KatoKyohei YamadaMai TakeuchiTakaharu SuzukiMayuko MoritsuboTakuya FurutaYoshitaka ImaizumiJun TakizawaKoji KatoJunji SuzumiyaRitsuro SuzukiKoichi OhshimaPublished in: Cancer medicine (2024)
The classification of PTCL-NOS into PTCL-TBX21 and PTCL-GATA3 is useful for predicting the prognosis of Japanese patients and stratifying the administration of tumor immune checkpoint inhibitors in clinical practice.